jRCT2031220104
Untitled Trial
PSMAddition: An International Prospective Open label, Randomized, Phase III Study comparing 177Lu PSMA 617 incombination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic HormoneSensitive Prostate Cancer (mHSPC) (PSMAddition)
Novartis Pharma. K.K.·Japan Registry Clinical TrialRecruitment Completed
Study focus
- Disease/Condition
- Prostate cancer
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Novartis Pharma. K.K.
- Location
- United States of America;Austria;Belgium;Canada;Denmark;France;South Korea;Netherlands;Poland;Singap
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Malignant neoplasm of prostateHyperplasia of prostateDisorder of prostate, unspecifiedOther disorders of prostateCarcinoma in situ: Prostate
Data source
- Registry
- Japan Registry Clinical Trial
- Trial ID
- jRCT2031220104
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for jRCT2031220104 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharma. K.K. and is currently Recruitment Completed. The study focuses on Prostate cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.